Dupixent is a biologic medication used to treat serious inflammatory conditions such as moderate to severe atopic dermatitis, asthma, and chronic sinus disease with nasal polyps. For many patients, it provides real relief when other treatments have failed. At the same time, a growing number of patients have reported severe eye problems, joint pain, and other serious reactions after starting Dupixent. When those side effects are persistent or vision threatening, it is reasonable to ask whether the risks were fully explained and whether the manufacturer did enough to protect patients.
Reports and prescribing information describe a range of potential side effects. Some patients develop significant eye and vision problems, including conjunctivitis, keratitis, dry eye, blurred vision, and sensitivity to light. Others experience eosinophilic conditions such as eosinophilic pneumonia or eosinophilic granulomatosis with polyangiitis, especially when oral steroids are reduced or stopped. There are also reports of serious joint and muscle pain, allergic reactions, skin rashes, and recurrent infections. While many side effects are temporary, some individuals are left with ongoing eye disease or systemic complications that change their daily lives.
Dupixent is usually given by injection every two weeks and is intended for long term use. Someone who responds to the drug may receive dozens or even hundreds of injections over several years. That long treatment course raises important questions about how clearly patients and prescribers were warned about the likelihood and severity of certain complications, particularly eye problems. Litigation often focuses on whether early referral to an eye specialist was strongly emphasized and whether patients had enough information to balance the benefits of symptom relief against the risk of serious side effects.
Clinical trials and real world data show that conjunctivitis and keratitis occur more often in patients treated with Dupixent than in those who received placebo, especially in atopic dermatitis populations. Most cases improve, but some patients go on to develop chronic eye disease, vision changes, or other complications that require ongoing specialist care. There are also reports of eosinophilic and immune mediated reactions that can be dangerous if not recognized and treated quickly. These concerns have led injured patients to seek accountability through product liability claims.
If you or someone you love began using Dupixent and later developed severe or persistent eye problems, eosinophilic pneumonia, EGPA, or other serious systemic reactions, you may have legal options. You should never stop or change a prescription medication without talking with your treating physician, but you do not have to face the legal and financial questions on your own.